arGEN-X BV, a Rotterdam, The Netherlands-based biopharmaceutical company focused on the discovery and development of human antibodies, announced that its newly formed R&D subsidiary arGEN-X BVBA has received a €1.3m grant to further develop its novel SIMPLE Antibody platform.
The grant was awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
arGEN-X’s SIMPLE Antibody (Superior Immunodiversity with Minimal Protein Lead Engineering) platform, as stated by Tim van Hauwermeiren, CEO of arGEN-X, “has the potential to rapidly create new product candidates both against novel therapeutic targets and against targets where standard antibody approaches fail to generate optimal lead diversity”.
“We are very pleased to receive this grant from the IWT, which, in conjunction with the substantial series A fundraising we completed recently, will allow us to continue the rapid development and validation of this exciting discovery platform”, he added.
Prof. Dr. Hans de Haard, CSO of arGEN-X, added: “This IWT grant will allow us to further develop the key competitive features of the SIMPLE Antibody platform and to initiate additional programs that are situated in the sweet spot of our proprietary antibody platform”.